Skip to main content
. Author manuscript; available in PMC: 2022 Jun 15.
Published in final edited form as: Clin Cancer Res. 2021 Oct 19;28(2):404–413. doi: 10.1158/1078-0432.CCR-21-2027

Table 3:

Summary of MMR immunohistochemistry, MSI polymerase chain reaction, tumor mutational burden and MSI Score/Sensor in Lynch Syndrome cohort

Case MMR Status
(IHC)
Second Hit in MMR genes
(MSK-IMPACT)
MSI Status
(PCR)
Signature Category
by
Exposure_SigMA
TMB
Score
(mut/Mb)
MSI
Score
MSI Sensor
1 Retained No MSS Aging 5.3 1.07 Stable (Liver Metastasis)
2 Retained No MSS HRD 3.5 0.05 Stable
3 Retained Yes (LOH) MSS N/A 2.6 0.58 Stable
4 Loss of MLH1 and PMS2, partial loss of MSH6 Yes (LOH) MSI MSI 16.7 7.24 Indeterminate
5 Retained No MSS APOBEC 3.5 0 N/A
6 Loss of MSH6 Yes (Somatic) Indeterminate MSI 20.2 3.56 Indeterminate
7 N/A N/A MSS Sig 17 3.5 0.25 Stable
8 Retained No MSS Aging 3.5 0.12 Stable
9 Retained N/A N/A N/A N/A N/A N/A
10 Loss of MSH2 and MSH6 No MSI MSI 24.84 11.5 High
11 Loss of MSH2 and MSH6 N/A N/A N/A N/A N/A N/A
12 Retained No MSS N/A 1.05 0.57 Stable
13 Loss of MLH1 and PMS2 Yes (LOH) MSI MSI 8.39 7.68 Indeterminate

Abbreviations: MMR, mismatch repair protein; IHC, immunohistochemistry; MSI, microsatellite instability; PCR, polymerase chain reaction; TMB, tumor mutational burden (somatic mutations per Megabase (mut/Mb); MSS, Microsatellite stable; LOH, loss of heterozygosity; HRD; Homologous repair deficiency; N/A, not available.